Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Alnylam Named to Bloomberg's Gender-Equality Index for 3rd Year in a Row

January 31, 2023

Alnylam Pharmaceuticals

The publication of the 2023 Bloomberg Gender-Equality Index (GEI) marks Alnylam's third consecutive year of inclusion in this prestigious and important diversity, equity and inclusion (DE&I) benchmark. It also represents an opportunity for us to reflect on our progress in DE&I and assess our efforts using the rich set of data and insights that the GEI report provides. 

Being recognized as part of the Bloomberg GEI for the third year in a row is exciting because it reflects our ongoing efforts to build a company that is truly committed to being diverse, equitable and inclusive. Our focus on ensuring that Alnylam is a workplace where women, and all employees, are supported, feel that they belong, and can thrive is core to our values and critical to our mission of bringing new treatments to patients living with rare and more common diseases." - Saraswathy (Sara) Nochur, Alnylam's Chief DE&I Officer 

The GEI is published annually by Bloomberg - a globally recognized business and financial information and news leader, as a resource for investors. The Gender-Equality Index standardizes, measures and contextualizes workplace gender metrics data supplied to Bloomberg voluntarily by companies.

According to Bloomberg, "the GEI tracks the performance of public companies committed to disclosing their efforts to support gender equality through policy development, representation and transparency.” 

Companies who submit for inclusion in the GEI (at no cost) use Bloomberg's standardized reporting framework. The GEI scoring methodology is comprised of two components: the amount of data disclosed and data excellence. According to Bloomberg, "Data excellence assesses a company’s performance against the key pillars of the GEI framework, in comparison with its industry peer group." Those five key pillars are:

  • Leadership & talent pipeline - measures the company's commitment to attracting, retaining and developing women for senior leadership positions
  • Equal pay & gender pay parity - addresses how a company is closing the gender pay gap through transparent and effective action plans
  • Inclusive culture - evaluates policies, benefits, and programs that contribute to an inclusive work environment in which all employees feel they are valued and have equal opportunities
  • Sexual harassment policies - assess sexual harassment policies and procedures
  • External brand - gauges how a company is perceived by stakeholders considering factors such as its supply chain, products and services, how women are portrayed in advertising, and external support for women in the community

 

There are also expanded areas of information requested to support the broader goal of providing more robust ESG (environmental, social, governance) data to investors. 

Included companies are not ranked. The 2023 GEI consists of 484 companies, headquartered in 45 countries and regions, across 11 sectors and 54 industries. Alnylam was one of just 33 healthcare sector companies selected to this year's list.  You can access the full list and Bloomberg's 2023 GEI Summary Report here.

From Bloomberg: 

The GEI serves as a touchstone for companies seeking to track their progress in gender inclusion and how the implementation of diversity policies shape company performance. A record number of companies disclosed their data for this year's GEI by using the GEI Framework, an increase of 11% year-over-year. 

“This year, GEI members’ disclosure for exploratory questions averaged at 92%, demonstrating collective interest in extending beyond gender inclusion metrics,” said Patricia Torres, Global Head of Bloomberg Sustainable Finance Solutions at Bloomberg. “The GEI continues to identify areas of impact for companies, helping to facilitate meaningful change that, ultimately, will contribute to more innovation, creativity, and higher performance.”

Learn more about the 2023 Bloomberg Gender-Equality Index and see the full report here, and Alnylam's commitment to Diversity, Equity and Inclusion here.

Tags

Careers & Culture, Articles, DE&I, Gender Equality, Bloomberg GEI

Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Careers & Culture 11 Years, 11 Insights: What The Boston Globe Top Place to Work Survey Reveals About Our ...
Careers & Culture Five in A Row! Alnylam Named a 2025 Best Workplace for Innovators by Fast Company
Careers & Culture Challenge Accepted: How Culture Powers Innovation at Alnylam
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site